Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513647 | 0.78 | CYP19A1 (0.31) | CYP19A1MBOAT4 | |
| SCHEMBL512921 | 0.78 | ESR1 (0.31) | CYP19A1MBOAT4 | |
| SCHEMBL5310137 | 0.71 | CYP19A1 (0.36) | CYP19A1MBOAT4 | |
| SCHEMBL514461 | 0.70 | CYP19A1 (0.38) | CYP19A1MBOAT4 | |
| SCHEMBL514463 | 0.66 | — | — | |
| SCHEMBL5489878 | 0.65 | CYP17A1 (0.42) | CYP19A1 | |
| SCHEMBL514561 | 0.65 | CYP17A1 (0.47) | CYP19A1 | |
| SCHEMBL5310140 | 0.65 | CYP19A1 (0.43) | CYP19A1MBOAT4 | |
| SCHEMBL513648 | 0.65 | CYP19A1 (0.37) | CYP19A1MBOAT4 | |
| SCHEMBL512922 | 0.65 | CYP19A1 (0.37) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586770-B2 | Unsaturated steroid compounds | Harbor Therapeutics, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2471536-A1 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Harbor BioSciences, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120029260-A1 | Screening and Treatment Method | BIOVIE INC. | 2012-02-02 | — | — | US | disclosed |
| US-20110137057-A1 | Unsaturated Steroid Compounds | BIOVIE INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110085984-A1 | Drug Product and Process for Making | BIOVIE INC. | 2011-04-14 | — | — | US | disclosed |
| US-7910755-B2 | Stem cell expansion and uses | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-1807118-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070077201-A1 | Stem cell expansion and uses | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070077203-A1 | Surrogate markers | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2007030124-A2 | TREATMENT SCREENING METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070053832-A1 | Drug product and process for making | BIOVIE INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | BIOVIE INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2006110172-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS.INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060088473-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-27 | — | — | US | disclosed |
| US-20060073099-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088473-A1 | Treatment screening methods | HSD3B1, HSD3B2, HSD17B11 | CYP19A1 17/4885MBOAT4 1296/4885 |
| US-20070077203-A1 | Surrogate markers | TSG101, RAD50, DNASE1L3 | CYP19A1 1330/4885MBOAT4 1995/4885 |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | CYP17A1, HSD17B11, HSD3B1 | CYP19A1 22/4885MBOAT4 2564/4885 |
| US-20110085984-A1 | Drug Product and Process for Making | CYP2D6, CYP3A5, CYP2B6 | CYP19A1 76/4885MBOAT4 1512/4885 |
| US-20060073099-A1 | Treatment screening methods | HSD17B11, HSD3B2, HSD3B1 | CYP19A1 6/4885MBOAT4 1432/4885 |
| US-20070053832-A1 | Drug product and process for making | CYP2D6, CYP3A5, CYP2B6 | CYP19A1 76/4885MBOAT4 1512/4885 |
| US-20070077201-A1 | Stem cell expansion and uses | NES, CD44, FGF2 | CYP19A1 4139/4885MBOAT4 3468/4885 |
| US-20110137057-A1 | Unsaturated Steroid Compounds | SREBF1, SREBF2, NR1H3 | CYP19A1 155/4885MBOAT4 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.